Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027)

• Status: Completed
• Trial end date: 2004-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will establish that the MK0431 100 mg anhydrous formulation tablets are bioequivalent to the MK0431 100 mg monohydrate final market image (FMI) tablets.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• Subject is in good health

• Female subjects must have a negative pregnancy test

• Subject is within 30% of ideal body weight

• Subject does not smoke

• Subject agrees to follow the study guidelines

Exclusion Criteria:

• Subject has a history of any illness that might confound the results of the study or make participation unsafe for the subject

• Subject has a history of hypoglycemia

• Subject has a history of any hepatic disease

• Subject is taking any oral, parenteral, topical or implantable contraceptives